PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 1 Diabetes Mellitus.
- Conditions
- Diabetes Mellitus, Type 1
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2007-02-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 320
- Registration Number
- NCT00424437
- Locations
- 🇨🇦
Pfizer Investigational Site, Laval, Quebec, Canada
A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT00424294
- Locations
- 🇺🇸
Pfizer Investigational Site, Ogden, Utah, United States
A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 135
- Registration Number
- NCT00422461
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Riser Medical Associates, Picayune, Mississippi, United States
🇺🇸Piedmont Medical Research Associates, Winston-Salem, North Carolina, United States
A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee
- Conditions
- OsteoarthritisChronic Pain
- Interventions
- Drug: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)Drug: Placebo
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 547
- Registration Number
- NCT00420992
- Locations
- 🇺🇸
Advanced Biomedical Research of America, Las Vegas, Nevada, United States
🇺🇸Community Research, Cincinnati, Ohio, United States
🇺🇸International Clinical Research Institute, Inc, Overland Park, Kansas, United States
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
- Conditions
- Lymphoma, Mantle-Cell
- Interventions
- Drug: PD-0332991
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 17
- Registration Number
- NCT00420056
- Locations
- 🇺🇸
New York Presbyterian Hospital, New York, New York, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Brigham & Women's Hospital, Boston, Massachusetts, United States
A Study Of The Effect Of CE-224535 On Knee OA (Osteoarthritis) Pain
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 212
- Registration Number
- NCT00418782
- Locations
- 🇺🇸
Pfizer Investigational Site, Spokane, Washington, United States
This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Inhaled Insulin (Exubera)Drug: Insulin glargine
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 413
- Registration Number
- NCT00418522
- Locations
- 🇵🇷
Pfizer Investigational Site, Carolina, Puerto Rico
A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2010-09-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT00417885
- Locations
- 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada
Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)
- Conditions
- Schizophrenia
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2009-10-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18239
- Registration Number
- NCT00418171
- Locations
- 🇺🇸
Pfizer Investigational Site, Whitehall, West Virginia, United States
Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain
- Conditions
- Pain
- Interventions
- Drug: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 467
- Registration Number
- NCT00415597
- Locations
- 🇺🇸
Stephen Miller, MD, Las Vegas, Nevada, United States
🇺🇸Steven Siwek, MD, Phoenix, Arizona, United States
🇺🇸Michael Loes, MD, Phoenix, Arizona, United States